Endovascular Treatment of Anterior Cranial Fossa Dural Arteriovenous Fistula.

IF 0.5
JNET Pub Date : 2025-01-01 Epub Date: 2023-05-26 DOI:10.5797/jnet.ra.2023-0018
Ichiro Nakagawa, Masashi Kotsugi, Shohei Yokoyama, Ryosuke Maeoka, Tomoya Okamoto, Hiromitsu Sasaki, Kenta Nakase, Ai Okamoto, Yudai Morisaki
{"title":"Endovascular Treatment of Anterior Cranial Fossa Dural Arteriovenous Fistula.","authors":"Ichiro Nakagawa, Masashi Kotsugi, Shohei Yokoyama, Ryosuke Maeoka, Tomoya Okamoto, Hiromitsu Sasaki, Kenta Nakase, Ai Okamoto, Yudai Morisaki","doi":"10.5797/jnet.ra.2023-0018","DOIUrl":null,"url":null,"abstract":"<p><p>Anterior cranial fossa (ACF) dural arteriovenous fistula (DAVF) is a rare lesion among cerebral DAVFs. This lesion shows significant bleeding risk because of the angioarchitecture, involving direct leptomeningeal retrograde venous drainage, as a nonsinus-type DAVF. Over the years, direct surgery has been considered the primary treatment for ACF DAVF, offering favorable clinical outcomes compared to a low complete obliteration rate with endovascular treatment and the relatively high risk of blindness due to central retinal artery occlusion with transophthalmic artery embolization. In recent years, however, significant improvements in DSA and 3D reconstruction imaging quality have allowed a much more precise understanding of the angioarchitecture of the shunt and vascular access route. In addition, advances in endovascular devices, including catheters and embolic materials, have facilitated microcatheter navigation into more distal vessels and more reliable closure of the fistulous point. Supported by such technological innovations, endovascular approaches to the treatment of ACF DAVF have been becoming successful first-line treatments. This article reviews the evolution of treatment strategies and the current status of endovascular treatment for ACF DAVF, with a particular focus on transarterial embolization.</p>","PeriodicalId":34768,"journal":{"name":"JNET","volume":"34 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826343/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNET","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5797/jnet.ra.2023-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Anterior cranial fossa (ACF) dural arteriovenous fistula (DAVF) is a rare lesion among cerebral DAVFs. This lesion shows significant bleeding risk because of the angioarchitecture, involving direct leptomeningeal retrograde venous drainage, as a nonsinus-type DAVF. Over the years, direct surgery has been considered the primary treatment for ACF DAVF, offering favorable clinical outcomes compared to a low complete obliteration rate with endovascular treatment and the relatively high risk of blindness due to central retinal artery occlusion with transophthalmic artery embolization. In recent years, however, significant improvements in DSA and 3D reconstruction imaging quality have allowed a much more precise understanding of the angioarchitecture of the shunt and vascular access route. In addition, advances in endovascular devices, including catheters and embolic materials, have facilitated microcatheter navigation into more distal vessels and more reliable closure of the fistulous point. Supported by such technological innovations, endovascular approaches to the treatment of ACF DAVF have been becoming successful first-line treatments. This article reviews the evolution of treatment strategies and the current status of endovascular treatment for ACF DAVF, with a particular focus on transarterial embolization.

颅前窝硬脑膜动静脉瘘的血管内治疗。
颅前窝(ACF)硬脑膜动静脉瘘(DAVF)是一种罕见的脑前颅窝病变。由于血管结构的影响,该病变具有明显的出血风险,包括直接轻脑膜逆行静脉引流,为非窦型DAVF。多年来,直接手术一直被认为是ACF - DAVF的主要治疗方法,相对于血管内治疗完全闭塞率低和经眼动脉栓塞导致视网膜中央动脉闭塞致盲的风险较高,手术治疗具有良好的临床效果。然而,近年来,DSA和3D重建成像质量的显著改善使得对分流血管和血管通路的血管结构有了更精确的了解。此外,血管内装置的进步,包括导管和栓塞材料,使得微导管导航到更远端的血管,更可靠地关闭瘘点。在这些技术创新的支持下,血管内方法治疗ACF - DAVF已成为成功的一线治疗方法。本文综述了ACF - DAVF治疗策略的演变和血管内治疗的现状,重点介绍了经动脉栓塞治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
38
审稿时长
17 weeks
期刊介绍: JNET Journal of Neuroendovascular Therapy is the official journal of the Japanese Society for Neuroendovascular Therapy (JSNET). The JNET publishes peer-reviewed original research related to neuroendovascular therapy, including clinical studies, state-of-the-art technology, education, and basic sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信